Tohoku University. Research Profiles

LANGUAGE
  • Top
  • Life Sciences
  • Development of a novel therapeutic drug, TMS-007, for acute cerebral infarction

Development of a novel therapeutic drug, TMS-007, for acute cerebral infarction

update:2018-12-17
  • JAPANESE
  • INQUIRY
The currently approved fibrynolytic therapy is only alteplase, but the use of it has been limited to 5% of patients with acute cerebral infarction due to possible side effects including hemorrhagic infarction that may be life-threatening. TMS-007 is a novel drug that has both fibrynolytic activity and brain protective effects. The aim of this project is to perform a clinical trial of this drug and to further achieve a commercial-based clinical use. We believe that this drug would contribute significantly in the treatment of acute cerebral infarction.



Researchers

Department of Neurosurgery, Graduate School of Medicine

TOMINAGA, Teiji , Professor
Doctor of Medicine

Keywords

List